Ultragenyx Pharmaceutical Inc (RARE) Expected to Post Quarterly Sales of $570,000.00

Wall Street brokerages predict that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will report $570,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings. The lowest sales estimate is $100,000.00 and the highest is $1.03 million. Ultragenyx Pharmaceutical posted sales of $10,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 5,600%. The business is scheduled to report its next earnings report on Thursday, February 15th.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $570,000.00 for the current fiscal year, with estimates ranging from $190,000.00 to $2.36 million. For the next fiscal year, analysts anticipate that the business will report sales of $45.88 million per share, with estimates ranging from $2.60 million to $226.60 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, meeting the consensus estimate of ($1.87). The firm had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.02 million. Ultragenyx Pharmaceutical’s quarterly revenue was up 81.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.64) earnings per share.

A number of research firms recently issued reports on RARE. Credit Suisse Group began coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday. They set an “outperform” rating and a $67.00 price objective for the company. BidaskClub cut shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday. Zacks Investment Research cut shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Raymond James Financial reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Friday, December 15th. Finally, Canaccord Genuity set a $80.00 price objective on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, December 5th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Ultragenyx Pharmaceutical currently has an average rating of “Hold” and a consensus price target of $72.06.

Shares of Ultragenyx Pharmaceutical (RARE) traded down $0.52 during trading hours on Friday, hitting $47.25. 420,100 shares of the stock traded hands, compared to its average volume of 419,708. The firm has a market cap of $2,030.00, a PE ratio of -6.78 and a beta of 1.83. Ultragenyx Pharmaceutical has a one year low of $43.14 and a one year high of $91.35.

Several large investors have recently bought and sold shares of RARE. Ameritas Investment Partners Inc. boosted its stake in Ultragenyx Pharmaceutical by 7.7% during the second quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 248 shares in the last quarter. Amalgamated Bank boosted its stake in Ultragenyx Pharmaceutical by 7.6% during the second quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock worth $309,000 after acquiring an additional 352 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Ultragenyx Pharmaceutical by 1.0% during the second quarter. Principal Financial Group Inc. now owns 73,412 shares of the biopharmaceutical company’s stock worth $4,559,000 after acquiring an additional 722 shares in the last quarter. California Public Employees Retirement System boosted its stake in Ultragenyx Pharmaceutical by 2.1% during the second quarter. California Public Employees Retirement System now owns 39,100 shares of the biopharmaceutical company’s stock worth $2,429,000 after acquiring an additional 800 shares in the last quarter. Finally, Swiss National Bank boosted its stake in Ultragenyx Pharmaceutical by 1.8% during the third quarter. Swiss National Bank now owns 67,252 shares of the biopharmaceutical company’s stock worth $3,582,000 after acquiring an additional 1,200 shares in the last quarter. 94.10% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/19/ultragenyx-pharmaceutical-inc-rare-expected-to-post-quarterly-sales-of-570000-00.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply